Altus Wealth Group LLC Sells 1,143 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Altus Wealth Group LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 8,294 shares of the biopharmaceutical company’s stock after selling 1,143 shares during the period. Altus Wealth Group LLC’s holdings in Pfizer were worth $220,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Pfizer during the 4th quarter valued at about $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. Fisher Asset Management LLC lifted its position in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock valued at $295,760,000 after purchasing an additional 4,938,209 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in shares of Pfizer by 28.5% during the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after purchasing an additional 4,726,549 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.5 %

Shares of Pfizer stock opened at $25.74 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market cap of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. The company has a 50-day moving average of $26.24 and a 200 day moving average of $27.13. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Get Our Latest Stock Report on PFE

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).